Previous Seminars
2023-2024
Applications of negative control analysis in pharmacoepidemiology (Zafar Zafari, MSc, PhD)
What does it take to improve medication safety? Lessons learnt in 15 years of research in ambulatory care (Tobias Dreischulte, MPharm, MSc, PhD)
Broadening the reach of the FDA sentinel system (Rishi Desai, MS, PhD)
Pharmacoepidemiology is better with laboratory data; Swedish experiences from the Stockholm CREAtinine Measurements (SCREAM) project (Juan-Jesus Carrerro, Pharm, PhD)
Evolution of a field: osteoporosis pharmacoepidemiology (Suzanne Cadarette, MSc, PhD)
Collaborating to Advance Health Equity in the World of Therapeutics (Christine Lee, PharmD, PhD and Julie Hsieh, PhD)
Post-marketing Pharmacovigilance (Judi Ng Cashin, MD)
Pharmacoepidemiology, Real-World Evidence and the Life Cycle of Drug Development (Susan Oliveria, ScD, MPH, FISPE)
Convergence of Benefit-Risk and Value: Implications for the Workforce of the Future (Frank Sifakis, PhD, MPH, MBA)
2022-2023
Addressing the Suicide Dilemma: The Challenge of Measuring Outcomes (Stanley Edlavitch, PhD, MA, FACE)
Accelerated Approval: Implications for Speed, Efficacy, Safety, and Public Health (Diana Zuckerman, PhD)
Real-World Evidence Using Routinely Collected Health Data; When is the Evidence Convincing? (Rolf Groenwold, PhD)
Optimizing Antihypertensive Treatment in 2023 to Prevent Cardiovascular Disease and Dementia: Lessons Using Pharmacoepidemiology (Adam Bress, PharmD, MS)
What You Need to Know about the Inflation Reduction Act (Stacie Dusetzina, PhD)
Too Many Medicines – The What, Why, and How of Deprescribing Research (Michael Steinman, MD)
An Online Tool for Correcting Risk Ratio or Cumulative Incidence Estimates for Bias Due to Outcome Misclassification (Vinay Mehta, PhD, MS)
Enhancing the Evidence on the Effectiveness and Safety of Diabetes Medications (Elisabetta Patorno, MD, DrPH)
Useful Population Findings in Pediatric Psychopharmacology (Daniel Safer, MD)
2021-2022
Real-world Data and Regulatory Decision Making for Post-market Drug Safety: Hydrochlorothiazide Use and Risk of Non-melanoma Skin Cancer (Darren Toh, ScD)
Pursuing Improved Drug Development and Use in CKD: Insights into Non-renal and Extracorporeal Clearance (Thomas D. Nolin, PharmD, PhD)
Determining the Comparative Benefits of New and Existing Drugs (Huseyin Naci, MHS, PhD)
Administrative Claims Data Linked to Cancer Registry Data: Opportunities to Measure Comorbidity and its Impact on Cancer Patient Survival (Angela Mariotto, PhD)
AI and Machine Learning in Healthcare: Challenges and Opportunities for Mitigating Bias and Promoting Fairness in Clinical Algorithms (Irene Dankwa-Mullan, MD, MPH)
Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance (Gerard Dal Pan, MD, MHS)
Pharmaceutical Reimbursement Nuances and Quality Implications for the Supply Chain (Joey Mattingly, PhD, PharmD, MBA)
Pregnancy Studies in the Context of FDA and EMA Guidance: Generating RWE for Assessing Pregnancy Safety (Sigal Kaplan, PhD)
Using mHealth to Measure Symptoms, Behavior, and Activity in Adolescents with Mood Disorders Treated with Antidepressants (Wendy Camelo Castillo, PhD)
2020-2021
Are Generic Drugs as Effective and Safe as the Brand Names? Results from a Canadian Research Program (Jacinthe Leclerc, RN, PhD)
Use of Real World Evidence in Regulatory Setting – Review of Strategy and Methodological Challenges (Douglas Kou, PhD, MPH, MA)
FDA’s Sentinel System: An Overview of the FDA’s Active Surveillance System for Medical Product Safety and Effectiveness (Sarah Dutcher, PhD, MS)
Use of Psychiatric Drugs in Nursing Homes: Impact of the COVID Pandemic (James Goodwin, MD)
Digital Therapeutics in Psychiatry: Novel Possibilities and New Considerations (Sunny Tang, MD)
Assessing the External Validity of Trial Results: Applications in Oncology (Jennifer Lund, PhD)
Mortality Risk of Antipsychotic Augmentation for Adult Depression: Context and Methodological Considerations (Tobias Gerhard, BSPharm, PhD)